ReviewFrontiers in neurology2019
Cognitive Impairment in Multiple Sclerosis With Regards to Disease Duration and Clinical Phenotypes.
Review in Frontiers in neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Association between emotion recognition and cognitive functioning in multiple sclerosis: a multilevel correlational meta-analysis.Scientific reports · 2026Pooled it
- Instruments measuring change in cognitive function in multiple sclerosis: A systematic review.Brain and behavior · 2023Pooled it
- Genes associated with grey matter volume reduction in multiple sclerosis.Journal of neurology · 2022Pooled it
- Memantine for Multiple Sclerosis: A Systematic Review and Meta-Analysis of Randomized Trials.Frontiers in neurology · 2020Pooled it
- Insomnia and inflammatory exposure impair spatial memory and cognitive mapping in older adults: a randomized controlled trial.Brain, behavior, and immunity · 2026Trial
- Cognitive training, exercise training or combined training? A comparative effectiveness research study on subjective and objective cognitive outcomes in multiple sclerosis.Journal of neurology · 2026Trial
- Randomised active controlled trial examining effects of aerobic exercise, cognitive and music interventions on depression, balance and mobility in schizophrenia.Scientific reports · 2025Trial
- Motor, cognitive, and combined rehabilitation approaches on MS patients' cognitive impairment.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023Trial
- Episodic memory deficits are associated with social cognitive impairments in multiple sclerosis.Journal of neurology · 2026Article
- What if it is the eyes? The effect of eye movement disorders on cognitive testing in MS.Journal of neurology · 2026Article
- Trajectories of processing speed in multiple sclerosis across disease-modifying therapies.Journal of neurology · 2026Article
- Sleep Disorders and Cognitive Function in Multiple Sclerosis: A Systematic Review of Polysomnographic Studies and Implications for Neurorehabilitation Strategies.Life (Basel, Switzerland) · 2026Review
- Structure-function multilayer network integration and cognition in multiple sclerosis.Network neuroscience (Cambridge, Mass.) · 2026Article
- Sensitivity and Specificity of a Revised Version of the TRACK-MS Screening Battery for Early Detection of Cognitive Impairment in Patients with Multiple Sclerosis.Biomedicines · 2025Article
- Composite Confirmed Disability Worsening/Progression Is a Useful Clinical Endpoint for Multiple Sclerosis Clinical Trials.Neurology · 2025Article
- Cognitive impairment, mood, and fatigue in various multiple sclerosis subtypes: a one-year follow-up study.Journal of neurology · 2025Article
- The role of CXCL12/CXCR4/CXCR7 axis in cognitive impairment associated with neurodegenerative diseases.Brain, behavior, & immunity - health · 2025Review
- No Relation Between Cognitive Impairment, Physical Disability and Serum Biomarkers in a Cohort of Progressive Multiple Sclerosis Patients.Biomolecules · 2025Article
- Alterations in neutrophil mRNA profiles in multiple sclerosis and identification of candidate genes for further investigation.Frontiers in neurology · 2025Article
- Face exploration, emotion recognition, and emotional enhancement of memory in relapsing-remitting multiple sclerosis.PloS one · 2025Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The relationships between cognitive impairment that exist during the clinical course of multiple sclerosis (MS) remain poorly described. The effect of disease duration has been studied in a few longitudinal cohorts and some cross-sectional studies that suggest that cognitive deficits tend to extend with disease duration. However, the effect of disease duration seems to be confounded by the effect of age. At the pre-clinical stage, cognitive deficits have been observed in patients with radiologically isolated syndromes, and their profile is similar than in clinically isolated syndromes (CIS) and relapsing-remitting MS (RRMS). The frequency of cognitive impairment tends to be higher in RRMS than in CIS. In these phenotypes, slowness of information processing speed (IPS) and episodic verbal and visuo-spatial memory deficits are frequently observed, but executive functions, and in particular verbal fluency, could also be impaired. More frequent and severe deficits are reported in SPMS than in RRMS with more severe deficits for memory tests, working memory and IPS. Similarly to what is observed in SPMS, patients with primary progressive MS (PPMS) present with a wide range of cognitive deficits in IPS, attention, working memory, executive functions, and verbal episodic memory with more tests and domains impaired than RRMS patients. Altogether these data suggested that not only the duration of the disease and age play an important role in the cognitive profile of patients, but also the phenotype itself, probably because of its specific pathological mechanism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.